1,485 results on '"Kim, Tae-You"'
Search Results
52. Data from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
53. Supplementary Figure 4 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
54. Supplementary Figures 1-2, Tables 1-2 from Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
55. Data from Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
56. Supplementary Figure Legend from RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
57. Supplementary Methods from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
58. Supplementary Figure 5 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
59. Supplementary Table 1. from Src as a Therapeutic Target in Biliary Tract Cancer
60. Data from Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin
61. Supplementary Data from Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
62. Supplementary Data from Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor–Immune Microenvironment in Colorectal Cancers
63. Supplementary Figures 1-3, Table 1 from Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma
64. Supplementary Figure 1 from Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression
65. Data from Enzastaurin, a Protein Kinase Cβ Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
66. Supplementary Figures 1-2 from Enzastaurin, a Protein Kinase Cβ Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
67. Supplementary Figure 3 from Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression
68. Supplementary Figure 2 from Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression
69. Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
70. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus)
71. Practical Utility of Liquid Biopsy for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer
72. The role of serial circulating tumor DNA for predicting clinical outcomes of chemotherapy in patients with advanced gastric cancer.
73. Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA
74. Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer
75. Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer
76. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib
77. Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
78. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer
79. Marketing strategies for fintech companies: text data analysis of social media posts
80. Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20‐year single‐center experience & propensity‐score matching
81. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
82. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
83. The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy
84. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial
85. Development and validation of the quality care questionnaire –palliative care (QCQ-PC): patient-reported assessment of quality of palliative care
86. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
87. Dynamic cohesin‐mediated chromatin architecture controls epithelial–mesenchymal plasticity in cancer
88. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer
89. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications
90. Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy
91. Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer
92. Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
93. MO41-4 Clinical utility of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC)
94. Abstract 5157: ctDNA change predicts treatment outcome of regorafenib in metastatic colorectal cancer
95. Abstract 5164: cell-free DNA (cfDNA) fragment size as a potential quantitative biomarker for metastatic colorectal cancer (mCRC)
96. Abstract 2800: Use of an optimized machine learning algorithm to develop DNA methylation markers for detecting colorectal cancer (CRC)
97. Nomogram Prediction of Survival and Recurrence in Patients With Extrahepatic Bile Duct Cancer Undergoing Curative Resection Followed by Adjuvant Chemoradiation Therapy
98. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
99. Perceived needs for the information communication technology (ICT)‐based personalized health management program, and its association with information provision, health‐related quality of life (HRQOL), and decisional conflict in cancer patients
100. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.